Weill Cornell Genitourinary Cancer Program

11/12/2025

Dr. Cora Sternberg spoke with Targeted Oncology about the evolution of combination therapies for metastatic hormone-sensitive :

During a live event, Cora N. Sternberg, MD, discussed the development of androgen receptor pathway inhibitors and takeaways from the ARANOTE trial in hormone-sensitive prostate cancer.

11/08/2025

At , Dr. Scott Tagawa spoke with ESMO - European Society for Medical Oncology as part of the Breaking Science video series about his Presidential Symposium presentation:

11/06/2025

Listen to Dr. Cora Sternberg discuss treatment options for hormone-sensitive and targeting the androgen-sensitive pathway on this via Future Oncology Taylor Francis:

This podcast examines how hormone-sensitive prostate cancer (HSPC) is treated, specifically looking at therapies that target the androgen-sensitive pathway. Identification of patients and the clini...

11/05/2025

Continuing coverage from : Learn more about the results Dr. Scott Tagawa presented on a lutetium Lu 177 vipivotide tetraxetan combination for a subset of patients:

Lutetium Lu 177 vipivotide tetraxetan plus an ARPI and ADT improved rPFS in metastatic hormone-sensitive prostate cancer.

11/03/2025

ICYMI: Dr. Scott Tagawa presented results at evaluating the ability of a radioligand therapy to slow hormone-sensitive progression

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of....

10/30/2025

Watch Dr. Scott Tagawa discuss the future of based on the existing data from the phase III PSMAddition trial for metastatic hormone-sensitive : https://bit.ly/4hv10IU (cc: GU Oncology Now )

Drs. Tagawa, Nizam continue their discussion on PSMAddition, focusing on safety outcomes and long-term implications.

10/28/2025

Dr. Scott Tagawa spoke with OncLive about the phase 3 for patients with prostate specific-membrane antigen ( )-positive metastatic hormone-sensitive that he presented at :

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

10/23/2025

From : Dr. Scott Tagawa shared results from a dose-escalation and expansion evaluating fractionated and multiple-dose -targeted alpha radionuclide 225Ac-J591 for metastatic castration-resistant :

ESMO 2025 multiple-dose PSMA-targeted alpha radionuclide 225Ac-J591 for metastatic castration-resistant prostate cancer (mCRPC).

10/22/2025

WATCH: Dr. Scott Tagawa spoke with Urology Times about key findings from the phase 3 PSMAddition he presented at

Scott Tagawa, MD, provides an overview of key findings from the PSMAddition study, evaluating 177Lu-PSMA-617 combined with ADT and ARPI in mHSPC.

10/21/2025

presented at by Dr. Scott Tagawa found that adding a radioligand therapy to standard of care for metastatic hormone-sensitive reduced progression or death risk by 28%: https://bit.ly/43xojvJ (cc: The American Journal of Managed Care)

New findings reveal that combining Pluvicto with standard therapies significantly improves outcomes for patients with prostate cancer, enhancing quality of life.

10/13/2025

New from Dr. Neal Patel and Weill Cornell Medicine colleagues found that a proportion of men diagnosed with low grade have a higher-risk disease than suggested by biopsy:

Prostate cancer-specific mortality rates 2.4 and 4.7 percent for unfavorable intermediate-risk and high-risk GG1.

10/09/2025

In another Urology Times video, Dr. Tim McClure outlined recent data on focal therapy with irreversible electroporation (IRE) for prostate tissue ablation:

Timothy D. McClure, MD, outlines key findings from the PRESERVE trial, which evaluated IRE for prostate tissue ablation in patients with intermediate-risk prostate cancer.